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This study was aimed at: (i) investigating the expression proﬁles of some antioxidant and epidermal growth factor receptor genes
in cancerous and unaﬀected tissues of patients undergoing lung resection for non-small cell lung cancer (NSCLC) (cross-sectional
phase), (ii) evaluating if gene expression levels at the time of surgery may be associated to patients’ survival (prospective phase).
Antioxidant genes included heme oxygenase 1 (HO-1), superoxide dismutase-1 (SOD-1), and -2 (SOD-2), whereas epidermal
growth factor receptor genes consisted of epidermal growth factor receptor (EGFR) and v-erb-b2 erythroblastic leukaemia viral
oncogene homolog 2 (HER-2). Twenty-eight couples of lung biopsies were obtained and gene transcripts were quantiﬁed by
Real Time RT-PCR. The average follow-up of patients lasted about 60 months. In the cancerous tissues, antioxidant genes were
signiﬁcantly hypo-expressed than in unaﬀected tissues. The HER-2 transcript levels prevailed in adenocarcinomas, whereas EGFR
in squamocellular carcinomas. Patients overexpressing HER-2 in the cancerous tissues showed signiﬁcantly lower 5-year survival
than the others.
1.Introduction
Lung cancer, in particular non-small cell lung cancer
(NSCLC), is the leading cause of cancer related deaths
worldwide, given its incidence and poor prognosis mainly
due to delay in diagnosis [1]. Molecular heterogeneity in
the genomics and/or proteomics of NSCLC may underlie a
diﬀerentclinicaloutcomeandresponsetotherapyofpatients
withsimilarclinicalstageandhistopathology.Amongmolec-
ular markers, expression proﬁles of antioxidant genes and
proto-oncogenes, identiﬁed by microarrays or quantitative
reverse transcriptase PCR (qRT-PCR), may signiﬁcantly
aﬀect the clinical outcome of NSCLC [2–4].
Oxidative stress plays a key role in both development
and progression of NSCLC. Reactive oxygen species (ROS)
can induce DNA damage that, if unrepaired, may lead to
disruption of gene transcription as well as to interference
with DNA methylation [5, 6]. On the other hand, ROS
may up-regulate transcription factors as MAP-kinase/AP-1
and NF-kB that, in turn, induce the expression of several
genes involved in key cellular pathways [7, 8]. Among
these, there is heme oxygenase-1 (HO-1), a microsomal
heat shock protein that catalyzes the ﬁrst and rate-limiting
step in heme catabolism and shows high inducibility by
several stimuli [9]. Expressed in airway epithelial cells
and alveolar macrophages, it displays both a cytoprotective2 Journal of Nucleic Acids
and antioxidant role [10]. Cytosolic and mitochondrial
superoxide dismutases (SOD-1 and SOD-2, resp.) play also a
prominent role in the pulmonary antioxidant defense system
[11], catalyzing the dismutation of superoxide anion to
hydrogenperoxideandwater.Experimentalevidenceisavail-
able showing that ROS may induce the ligand independent
phosphorylation of the Epidermal Growth Factor Receptor
(EGFR) through oxidized src kinases [12, 13]. Moreover,
the expression of the receptor is induced in conditions of
oxidative stress [14]. The EGFR belongs to the ErbB family
of transmembrane receptors including at least four isoforms,
namely erbB-1 (EGFR), erbB-2 (HER-2), erbB-3 (HER3),
and erbB-4 (HER4), whose role in lung carcinogenesis as
oncogenes is generally accepted [15]. Following the binding
of epidermal growth factor (EGF)-like ligands, these recep-
tors homo/hetero-dimerize on the cell surface and activate
the cytosolic tyrosine-kinase domain, with downstream
stimulation of intracellular signalling pathways, which are
essential for cancer development and progression [16, 17].
Both EGFR and HER-2, having an 85% homology in amino
acid residues, trigger similar down stream signal event.
There are no known ligands for HER-2 that is the preferred
heterodimerization partner of this family of receptors [16].
The main aim of the present study was to evaluate dif-
ferences in the expression proﬁles of antioxidant (HO-1,
SOD-1, SOD-2) and epidermal growth factor genes (EGFR,
HER-2) in both cancerous and unaﬀected lung tissues of
clinical early-stage NSCLC patients.
As a further aim, we evaluated the inﬂuence of gene exp-
ression levels at the time of surgery on further patients’
survival.
2.MaterialsandMethods
2.1. Study Design. This was an observational study on
consecutivepatientswithasinglelunglesioneitherprovenor
suspected to be an early clinical stage (I or II) of NSCLC and
undergoing lung resection with curative intent. The study
was both cross-sectional and prospective in nature. In the
cross-sectionalphase,weevaluatedthegeneexpressionlevels
in both cancerous and unaﬀected lung tissues, whereas in
the prospective phase, we evaluated the inﬂuence, if any, of
gene expression levels at the time of surgery on the patients’
survival times.
Patients’enrollmentproceededfromJunetoAugust2002
and from April 2003 to April 2004, with the interruption
being due to a temporary lack of adequate systems of
biopsy storage. Exclusion criteria were clinical T3 tumors
and a history of malignancy in the previous 5 years.
Informed consent was obtained from each patient at the
time of enrollment, and sample collection and storage were
performed according to the principles laid down in the
Declaration of Helsinki (1964). The study received approval
by the local Ethics Committee.
Preoperative work-up included medical history and
examination, oncological staging and functional evaluation.
All patients were staged by chest and abdomen CT scans;
in addition, brain CT scan, abdominal ultrasound, or
bone scintigraphy were performed if indicated. Any death
occurring within 30 days from surgery or during the same
hospitalization was deﬁned as postoperative mortality and
cases were excluded from survival analysis.
Survival was calculated from the day of surgery to death
or last follow-up (1 April 2008), provided that patients did
not receive any palliative therapy.
2.2. Sample Collection and Storage. Small pieces (about 0.5–
1cm 3) of lung biopsies, from both cancerous and unaﬀected
tissues of the resected specimen, were collected into tubes
containing the RNAlater reagent (Ambion Inc., Austin, TX,
USA) and stored at −80
◦C until analysis. Unaﬀected tissue
samples underwent intraoperative frozen section examina-
tion to exclude tumor inﬁltration.
2.3. RNA Isolation and cDNA Synthesis. Total RNA was
isolated by the TRIzol reagent (Invitrogen, Carlsbad, CA,
USA) and digested with DNase I (DNA-free, Ambion Inc.,
Austin, TX, USA). RNA quality was checked by 1% TBE
agarosegelelectrophoresis,usingadenaturingloadingbuﬀer
(RNALadder,NewEnglandBiolabsInc.,Beverly,MA,USA).
Total RNA quantiﬁcation was carried out by the RiboGreen
probe (Molecular Probes, Eugene, OR, USA) on a Cary
Eclipse ﬂuorescence spectrophotometer equipped with a
microplate reader (Varian Inc, Scientiﬁc Instruments, Palo
Alto, CA, USA). cDNA was synthesized using 250–500ng of
total RNA, 250ng of random exhamer primers (Invitrogen,
Carlsbad, CA, USA), and 200U of SuperScript II Reverse
Transcriptase(Invitrogen,Carlsbad,CA,USA),followingthe
manufacturer’s recommended experimental conditions.
2.4. Gene Expression. HO-1, SOD-1, SOD-2, EGFR, and
HER-2 gene expression was assessed by Real-Time qRT-
PCR on an iCycler iQ Multicolor RealTime PCR Detection
System (Bio-Rad, Hercules, CA, USA). The PCR mixture
contained 2μL of template cDNA, 400nM of primers, 100
nM of FAM-conjugated Universal Probe (Roche, Diagnostic
Mannheim, Germany), and 2× QuantiTect Probe RT-PCR
Master Mix (Qiagen, Hilden, Germany) and water to 25 μL.
Table 1 presents the speciﬁc primers, spanning the exon-
exon junctions, and probes, designed by the ProbeFinder
software (Roche Diagnostics, Mannheim, Germany). The
ampliﬁcation protocol consisted of 15 minutes at 95
◦C
followed by 40 cycles at 94
◦C for 20 s and at 60
◦Cf o r1
minute. Duplicate assays were run for each sample and each
plate included a standard curve and a negative control.
The relative transcript quantiﬁcation was calculated by
the geNorm algorithm for Microsoft Excel [18]a f t e rn o r -
malization with β2-microglobulin (β2M), phosphoglycerate
kinase 1 (PGK1), succinate dehydrogenase complex subunit
A (SDHA), hypoxanthine-guanine phosphoribosyltransferase
(HPRT), and ribosomal protein L13 (RPL13) genes, and
expressed in terms of arbitrary units (a.u.).
2.5. Statistical Analysis. Statistical analysis was performed
by the SPSS 15.0 for Windows software. Variables were not
normally distributed, also after logarithmic transformation,Journal of Nucleic Acids 3
Table 1: Nucleotide sequences for primers and probes used in the present study.
Genes Forward primers Reverse primers Probes
SOD-1 5 TCATCAATTTCGAGCAGAAGG3  5 CAGGCCTTCAGTCAGTCCTTT3  5 FAM TGGGGAAG3 DQ
SOD-2 5 TGGTGGAGAACCCAAAGG3  5 GTCAAAGGAACCAAAGTCACG3  5 FAM GCTGGAAG3 DQ
HO-1 5 GGGTGATAGAAGAGGCCAAGA3  5 AGCTCCTGCAACTCCTCAAA3  5 FAM CATCCAGC3 DQ
EGFR 5 ACACAGAATCTATACCCACCAGAGT3  5 ATCAACTCCCAAACGGTCAC3  5 FAM TCTGGAGC3 DQ
HER-2 5 GATCCGGAAGTACACGATGC3  5 GCTCCGCTAGGTGTCAGC3  5 FAM TGGTGGAG3 DQ
PGK1 5 GGAGAACCTCCGCTTTCAT3  5 CTGGCTCGGCTTTAACCTT3  5 FAM GGAGGAAG3 DQ
B2M 5 TTCTGGCCTGGAGGCTATC3  5 TCAGGAAATTTGACTTTCCATTC3  5 FAM CATCCAGC3 DQ
SDHA 5 AGAAGCCCTTTGAGGAGCA3  5 CGATTACGGGTCTATATTCCAGA3  5 FAM GGAGGAAG3 DQ
HPRT 5 TGACCTTGATTTATTTTGCATACC3  5 CGAGCAAGACGTTCAGTCCT3  5 FAM GCTGAGGA3 DQ
RPL13 5 ACAGCTGCTCAGCTTCACCT3  5 TGGCAGCATGCCATAAATAG3  5 FAM CAGTGGCA3 DQ
Legend: FAM = ﬂuorescein; DQ = dark quencher dye.
hence data were analyzed by nonparametric tests. Com-
parisons between two independent or two related samples
were performed by the Mann-Whitney U or the Wilcoxon’s
test. The ratios of gene expression levels in the cancerous
versus the unaﬀected tissues were recoded into dichotomic
variables (values up to or higher than one) that were used to
evaluate survival curves by the Kaplan Meyer analysis with
log-rank (Mantel-Cox) test. The Cox regression analysis was
used to study the eﬀect of multiple covariates on survival
curves. Two patients deceased for causes surely unrelated
to NSCLC (a postoperative death and pulmonary embolism
after discharge) were excluded from analyses of survival.
3. Results andDiscussion
Duringthestudyperiod,89patientswereadmittedatasingle
center as aﬀected by a lung lesion proven or suspected to
be an NSCLC at clinical stage I or II. Of these: 10 were
excluded for clinical stage T3N0M0 and 15 for a history
of malignancy in the previous 5 years. Nine patients did
not give consent to the study, thus 55 were enrolled. In
eight cases, the lung lesion was too small (1.5cm maximum
diameter) or completely endobronchial, so that the surgeon
did not perform any biopsy in order not to spoil the ﬁnal
pathology exam. Of the 47 patients undergoing biopsy, 19
were weeded out because frozen section on the nodule
revealed benign lesions (n = 7) or metastases from another
primary site (n = 7) or carcinoid tumors (n = 5). Therefore,
28 couples of biopsies (cancerous and unaﬀected tissues)
constitute the ﬁnal study sample. There were 5 females and
23 males, mean aged 70 years (range 55–82). Twenty-six
out of 28 were either previous or current smokers, with
a mean tobacco exposure of 50.5pack/years. Twenty-four
lobectomies, three pneumonectomies, and one anatomical
segmentectomy were performed, associated with standard
lymphadenectomy. There were 14 adenocarcinomas (ADC),
13 squamous cell carcinomas (SCC), and 1 undiﬀerentiated
carcinoma. Despite all patients were clinically stage I or II
at preoperative examinations, ﬁnal pathology [19] revealed
the following: stage I in 20 cases (6 stage Ia and 14 stage Ib),
stage II in 5 (1 IIa and 4 IIb), and stage IIIa in 3. None of
Table 2: Distribution of gene transcript levels (medians and
interquartile (25th–75th) ranges of values in arbitrary units, a.u) in
cancerous and unaﬀected tissues. Results of paired sample analysis
(Wilcoxon’s test) are shown (P).
Gene Cancerous tissue, Unaﬀected tissue, P
transcripts a.u. a.u.
HO-1 0.10 (0.07–0.15) 0.16 (0.13–0.22) .031
SOD-1 0.13 (0.09–0.15) 0.18 (0.14–0.19) .006
SOD-2 0.17 (0.09–0.23) 0.26 (0.18–0.36) .001
EGFR 0.07 (0.04–0.09) 0.05 (0.03–0.07) .258
HER-2 0.23 (0.09–0.37) 0.23 (0.16–0.35) .228
the patients received adjuvant therapy or any patient was lost
at follow-up. At the time of data analysis (70 months after
the ﬁrst patient was enrolled), 14 (50%) of the patients had
died: 12 by disease recurrence and two by tumor unrelated
causes, by postoperative death and pulmonary embolism
after discharge, respectively. The overall 5-year survival was
50% and it became 56% if considering only stage I and II
patients. Median follow-up for the 14 patients alive was 58.9
months (range 48–70).
Table 2 shows the average levels of investigated tran-
s c r i p t sb o t hi nc a n c e r o u sa n du n a ﬀected lung tissues. In two
cases, we failed to characterize the transcript levels, because
of poor quality RNA.
The HO-1, SOD-1, and SOD-2 transcript levels were
signiﬁcantly lower in the cancerous tissue, whereas no
signiﬁcantdiﬀerencewasapparentforbothEGFRandHER-2
mRNA levels. After stratiﬁcation of patients by histopathol-
ogy(25subjects,excludingtheonlypatientwithdiagnosison
undiﬀerentiated carcinoma), some diﬀerence was apparent
only for EGFR and HER-2 transcripts. The levels of HER-2
mRNA were signiﬁcantly higher in ADC than SCC tumor
samples (median values of 0.38 (interquartile range 0.24–
0.51) a.u. versus 0.10 (0.07–0.13) a.u., P<. 001), whereas
the diﬀerence was not signiﬁcant for the EGFR transcript
(Figure 1(a)). Figure 1(b) shows the ratios of EGFR and
HER-2 transcript levels in the cancerous versus unaﬀected
tissues. EGFR levels prevailed signiﬁcantly in subjects with4 Journal of Nucleic Acids
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Figure 1: (a) EGFR and HER-2 transcript levels (as arbitrary units, a.u.) in squamocellular carcinoma (SCC) and adenocarcinoma (ADC)
samples. Lines represent medians of values. (b) Expression ratio levels of the same genes in the cancerous (C.T.) versus unaﬀected tissues
(U.T.). Lines represent medians of values.
SCC as compared to those with ADC (median values of 1.59
(interquartile range 1.00–2.93) a.u. versus 0.72 (0.53–1.08)
a.u., P = .019), whereas the opposite held true for HER-2
(median values of 1.06 (interquartile range 0.62–2.82) a.u.
versus 0.46 (0.33–1.14) a.u., P = .019).
Then, we proceeded to analyze the survival times on
24 patients (in two cases, gene expression results were
unavailable and two cases were excluded, given their death
bycancerunrelatedcauses).Table 3 showsthatsubjectsover-
expressing HER-2 in the cancerous tissue as compared to the
unaﬀected one displayed survival times about three times
lower, on average, than the rest of subjects. In agreement
with this, 5-year survivors showed signiﬁcantly lower HER-2
transcript levels in the cancerous versus the unaﬀected tissue
than patients dead within 5 years from surgery (medians
(interquartile ranges) of 0.48 (0.32–0.73) a.u. versus 1.39
(0.70–2.95) a.u., P<. 05).
The eﬀect of the HER-2 transcript ratio on survival was
conﬁrmed by the Kaplan Meier analysis (Figure 2). A Cox
regression model including also age, sex, tumor stage, and
histology as covariates conﬁrmed the role of HER-2 tran-
script ratio as main factor (P = .012) aﬀecting the patients’
survival, whereas other covariates showed no eﬀect. In the
same model, the strength of association between longer
survival times and HER-2 transcript ratio values higher than
1 was 11.42 (95% conﬁdence interval: 1.74–74.84).
The present study shows that the expression levels of
genes displaying antioxidant and cytoprotective properties,
such as SOD-1, SOD-2, and HO-1, are depressed in lung
cancer as compared to the unaﬀected lung tissue. These
results indirectly conﬁrm the association of oxidative stress
with the neoplastic phenotype. Superoxide dismutases are
generally regarded as ﬁrst line antioxidant enzymes, given
their unique role in detoxiﬁcation of superoxide radicals.
Previous studies investigating on SOD expression in human
lung cancer produced variable results (reviewed in [20]).
With the exception of one study, ﬁnding raised SOD-2 (and
not SOD-1) transcript levels (by Northern blot analysis) inJournal of Nucleic Acids 5
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Figure 2: Kaplan-Meier plot of survival times in NSCLC patients
classiﬁedbyexpressionratiolevelsofHER-2transcriptincancerous
versusunaﬀectedtissues(uptoorhigherthanone).Thedashedline
represents subjects over-expressing HER-2 mRNA in the cancerous
versus unaﬀected tissues, whereas the continuous line indicates
subjects with lower expression levels of HER-2 mRNA in cancerous
versusunaﬀectedtissuesamples.Crossesindicatecensoredsubjects,
represented by patients still alive at 1st April 2008.
Table 3: Average survival times in subjects classiﬁed according
to the expression levels of diﬀerent transcript in cancerous (C.T.)
versus unaﬀected (U.T.) tissues. Medians and interquartile (25th–
75th) ranges of values are shown, as well as the results of the Mann-
Whitney U test (P).
Transcripts Survival (months) P
C. T. / U.T >1 C .T ./U . T≤ 1
HO-1 48.00 (33.00–63.00) 48.00 (16.50–59.00) .659
SOD-1 52.50 (11.00–60.00) 48.00 (17.50–63.00) .865
SOD-2 18.00 (14.50–57.00) 49.00 (20.25–59.50) .303
EGFR 51.50 (17.75–59.50) 48.00 (16.50–64.50) .843
HER-2 19.00 (15.00–48.00) 56.50 (41.25–66.00) .019
the cancerous, as compared to unaﬀected tissue [21], the
others investigated either whole SOD activity, irrespective
of isoenzymes, or SOD proteins (by immunohistochemistry
(IHC) or Western blot). Some criticism has been raised
aboutthespeciﬁcityofantibodiestoSOD-2[20].Ourresults
are consistent with the experimental observation that SOD
activity may suppress the malignant phenotype [20].
The role of HO-1 in carcinogenesis has not yet been
well elucidated [22]. Our data support the hypothesis that
the expression of the enzyme is defective in lung cancer
tissue and are in agreement with a recent study [23] showing
reduced HO-1 expression (by IHC methods) in the alveolar
macrophages of patients with NSCLC, as compared to
controls.
Overexpression of EGFR and HER-2 receptors in NSCLC
samples has been reported in many series, ranging from 43
to 89% and from 16 to 57% of tumors and patients, respec-
tively (reviewed in [24]). Inconsistent results may reﬂect
diﬀerences in analytical techniques, procedures, and study
populations.Severalmethodsareavailabletoevaluatethetis-
sue expression of these receptors, including those looking at
proteins (IHC, Western blotting or enzyme immunoassay),
RNA (Northern blot analyses and RT-PCR), or DNA (ﬂuo-
rescence in situ hybridization (FISH) or quantitative PCR)
levels. The most commonly used technique was IHC, whose
standardization is far to be achieved [25]. The Real-Time
qRT-PCR we used for our analyses is an accurate technique
that may allow the direct comparison of expression levels of
target genes in both the cancerous and unaﬀected tissues.
Our study, even demonstrating similar expression proﬁles
of EGFR and HER-2 in cancerous and unaﬀected tissues,
conﬁrmed that EGFR is overexpressed in SCC, as compared
to ADC samples, whereas HER-2 displays an opposite
behaviour [25, 26]. This may have therapeutic consequences,
as both the proteins have been validated as clinically relevant
targets, and several diﬀerent types of agents inhibiting these
receptors are currently under development [27].
In this study, the overall ﬁve-year survival rate (56%
considering only patients at stages I and II) was consistent
with previous observation [19, 28]. However, the HER-
2 expression ratio in the cancerous versus the unaﬀected
tissue was a signiﬁcant predictor of the 5-year prognosis.
At the time of surgery, ﬁve-year survivors showed values
of HER-2 transcript ratio that were on average about 30%
of the values observed in patients undergoing death. At
the end of the follow-up period, subjects over-expressing
the receptor in the cancerous tissue were deceased by 80%,
whereas those with lower expression ratios were still alive
by 80%. The Cox multivariate analysis allowed us to exclude
any interference by tumor stage, histology, and age. A main
limitation of this study was its small sample size. However,
the extent of deviation from expected 5-year survival in both
the patient groups ensures the statistical power of the results
(alpha = 5%, beta = 80%). Our data are in agreement with
previous studies, mostly relying on IHC characterizations
and giving a meta-analytical hazard ratio of 1.5 (95%
conﬁdenceinterval1.29–1.86)forworseprognosisassociated
to HER-2 overexpression [24]. The mechanisms linking
HER-2 expression to a bad prognosis rely on a pleiotropic
cascade of eﬀects secondary to HER-2 activation. These
include (i) increase of cell proliferation and survival and per-
turbation of diﬀerentiation, dependent on the activation of
the phosphatidylinositol 3-kinase-AKT and the ras/mitogen-
activated protein kinase pathways [29, 30], (ii) increased
angiogenesis, as a consequence of the ability of HER-2 to
modulate the equilibrium between proangiogenic (VEGF,
IL-8, angiopoietin-2) and antiangiogenic factors [31].
4. Conclusions
Obtained results demonstrate that in biopsy samples from
clinical early NSCLC, the expression levels of some antiox-
idant genes are depressed as compared to the surrounding
healthy tissue. Interestingly, the patients’ prognosis shows
a signiﬁcant inverse association to the ratio of HER-2
transcriptlevelsinthecancerousversustheunaﬀectedtissue.
However, owing to the small sample size, caution must
be exercised in the interpretation of results that are to be6 Journal of Nucleic Acids
considered as preliminary. Further conﬁrmation by larger
studies is needed, before observed ﬁndings may be translated
into biomarkers useful to improve clinical managing of
NSCLC cases.
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